Sign In
Buy BEAT
BioTelemetry Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.120 |
| EPS Surprise | 14.29% |
| Revenue estimate | 149.75K |
| Revenue actual | - |
| Release date | Mar 12, 2026 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.140 |
| EPS Surprise | -7.69% |
| Revenue estimate | 1.192M |
| Revenue actual | - |
| Release date | Nov 13, 2025 |
| EPS estimate | -$0.160 |
| EPS actual | -$0.150 |
| EPS Surprise | 6.25% |
| Revenue estimate | 875K |
| Revenue actual | - |
| Release date | Aug 13, 2025 |
| EPS estimate | -$0.160 |
| EPS actual | -$0.150 |
| EPS Surprise | 6.25% |
| Revenue estimate | - |
| Revenue actual | - |
Last 4 Quarters for BioTelemetry
Below you can see how BEAT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 13, 2025 |
| Price on release | $1.20 |
| EPS estimate | -$0.160 |
| EPS actual | -$0.150 |
| EPS surprise | 6.25% |
| Date | Price |
|---|---|
| Aug 07, 2025 | $0.94 |
| Aug 08, 2025 | $0.98 |
| Aug 11, 2025 | $0.94 |
| Aug 12, 2025 | $1.20 |
| Aug 13, 2025 | $1.20 |
| Aug 14, 2025 | $1.11 |
| Aug 15, 2025 | $1.03 |
| Aug 18, 2025 | $1.19 |
| Aug 19, 2025 | $1.10 |
| 4 days before | 28.18% |
| 4 days after | -8.33% |
| On release day | -7.50% |
| Change in period | 17.50% |
| Release date | Nov 13, 2025 |
| Price on release | $1.57 |
| EPS estimate | -$0.160 |
| EPS actual | -$0.150 |
| EPS surprise | 6.25% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $1.65 |
| Nov 10, 2025 | $1.69 |
| Nov 11, 2025 | $1.72 |
| Nov 12, 2025 | $1.67 |
| Nov 13, 2025 | $1.57 |
| Nov 14, 2025 | $1.56 |
| Nov 17, 2025 | $1.54 |
| Nov 18, 2025 | $1.70 |
| Nov 19, 2025 | $1.66 |
| 4 days before | -4.85% |
| 4 days after | 5.73% |
| On release day | -0.637% |
| Change in period | 0.606% |
| Release date | Mar 12, 2026 |
| Price on release | $1.47 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.140 |
| EPS surprise | -7.69% |
| Date | Price |
|---|---|
| Mar 06, 2026 | $1.40 |
| Mar 09, 2026 | $1.48 |
| Mar 10, 2026 | $1.35 |
| Mar 11, 2026 | $1.36 |
| Mar 12, 2026 | $1.47 |
| Mar 13, 2026 | $1.36 |
| Mar 16, 2026 | $1.27 |
| Mar 17, 2026 | $1.30 |
| Mar 18, 2026 | $1.26 |
| 4 days before | 5.00% |
| 4 days after | -14.29% |
| On release day | -7.48% |
| Change in period | -10.00% |
| Release date | May 13, 2026 |
| Price on release | $1.01 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.120 |
| EPS surprise | 14.29% |
| Date | Price |
|---|---|
| May 07, 2026 | $0.87 |
| May 08, 2026 | $0.89 |
| May 11, 2026 | $0.89 |
| May 12, 2026 | $0.91 |
| May 13, 2026 | $1.01 |
| May 14, 2026 | $1.04 |
| May 15, 2026 | $0.97 |
| May 18, 2026 | $0.96 |
| May 19, 2026 | $0.90 |
| 4 days before | 16.01% |
| 4 days after | -10.56% |
| On release day | 2.97% |
| Change in period | 3.76% |
BioTelemetry Earnings Call Transcript Summary of Q1 2026
HeartBeam executed on commercialization and R&D in Q1 2026. Commercially, the company signed anchor partnerships with ClearCardio and Atelier Health, establishing flagship presence in New York City, Dallas, South Florida and Southern California and targeting a premium direct-pay concierge market (estimated ~150,000 patients; breakeven target ~30,000 patients). Pricing guidance remains in the $750–$1,000 annual subscription range. Product development: completed first working prototype of an on-demand 12-lead patch and initiated a ~50-patient European pilot for ischemia detection; the patch aims to be a best-in-class 12‑lead extended-wear monitor in a $2B market. Clinical and AI: ALIGN-ACS pilot (100–120 ER chest-pain patients) is enrolling ahead of schedule and expected to finish enrollment by end of Q3 2026; a larger HEADSTART-ACS study (~500 patients, Indonesia-sponsored) is planned; collaboration with Mount Sinai to develop MI detection and wellness AI models is underway. Financials: closed an $11.5M financing in April (including overallotment), leaving pro forma cash ~ $12.4M; Q1 net loss $4.7M and operating cash outflow $3.6M (19% YoY reduction). Management now expects 2026 cash outflow to be below $16M, providing runway into 2027. Near-term revenue will be modest (some Q2 revenue expected) as the company focuses on validating adoption in anchor accounts in H1 2026 and scaling in H2 2026 toward 2027 growth.
